EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)Klinische Studie (Phase III)Open Access · CC BY 4.0

Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg

Eva Natukunda iD, Aditya H Gaur, Pope Kosalaraksa, Elizabeth Hellström, Renate Strehlau, Afaaf Liberty, Stephanie Cox, Rory Leisegang, Ramesh Palaparthy, Susanne Crowe, Vinicius Vieira, Kathryn Kersey und 1 weitere

Journal of the International AIDS Society · 2025

DOI: 10.1002/jia2.26414 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the International AIDS Society, 2025. Verfasst von Eva Natukunda und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Joint Clinical Research Centre, Kampala, Uganda. Hauptthemen laut MEDLINE: Adenine, Anti-HIV Agents, HIV Infections, Tenofovir. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Gilead Sciences, Inc., Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) was efficacious and well tolerated in children/adolescents with HIV (aged ≥6 years, weighing ≥25 kg) in a Phase 2/3 study. Here, we report data from children aged ≥2 years and weighing ≥14–

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenineAnti-HIV AgentsHIV InfectionsTenofovirAdolescentChildChild, PreschoolFemaleHumansMaleAlanineBody WeightCD4 Lymphocyte CountCobicistatEmtricitabineQuinolonesTreatment OutcomeDrug Combinations

Stichwörter der Autor:innen

E/C/F/TAFHIV‐1antiretroviral therapychildrenelvitegravirtenofovir alafenamide

Substanzen

AdenineAlanineAnti-HIV AgentsCobicistatelvitegravirEmtricitabineQuinolonesTenofovirtenofovir alafenamideDrug Combinations

Autor:innen und Institutionen

  • Department of Paediatrics, Joint Clinical Research Centre, Kampala, Uganda.
  • Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Be Part Yoluntu Centre, Paarl, South Africa.
  • Department of Paediatrics and Child Health, University of the Witwatersrand, Johannesburg, South Africa.
  • Chris Hani Baragwanath Hospital, Johannesburg, South Africa.

ORCID-Profile: Eva Natukunda

Förderung

  • NIAID NIH HHS
  • Gilead Sciences, Inc.
  • Gilead Sciences

Zitieren

APA

Natukunda, E., Gaur, A. H., Kosalaraksa, P., Hellström, E., Strehlau, R., Liberty, A., Cox, S., Leisegang, R., Palaparthy, R., Crowe, S., Vieira, V., Kersey, K., & Rakhmanina, N. (2025). Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.26414

Vancouver

Natukunda E, Gaur AH, Kosalaraksa P, Hellström E, Strehlau R, Liberty A, et al. Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg. Journal of the International AIDS Society. 2025. doi:10.1002/jia2.26414

BibTeX
@article{Natukunda2025,
  author = {Natukunda, Eva and Gaur, Aditya H and Kosalaraksa, Pope and Hellström, Elizabeth and Strehlau, Renate and Liberty, Afaaf and Cox, Stephanie and Leisegang, Rory and Palaparthy, Ramesh and Crowe, Susanne and Vieira, Vinicius and Kersey, Kathryn and Rakhmanina, Natella},
  title = {Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg},
  journal = {Journal of the International AIDS Society},
  year = {2025},
  doi = {10.1002/jia2.26414}
}
Kostenlos starten →